Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alteplase - Boehringer Ingelheim

Next Previous
Drug Profile

Alteplase - Boehringer Ingelheim

Alternative Names: Actilyse; Activacin; Activase; Cathflo; G-11021; G-11035; G-11044; GMK-527; GRTPA; IV rt-PA; Recombinant tissue plasminogen activator - Boehringer; RG-3626; rt-PA - Boehringer; rTPA - Boehringer; t-PA - Boehringer; Tissue plasminogen activator - Boehringer; Tissue type plasminogen activator - Boehringer

Latest Information Update: 22 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Genentech; John Hopkins University; Washington University School of Medicine
  • Class Anti-ischaemics; Antihaemorrhagics; Antithrombotics; Cardiovascular therapies; Plasminogen activator enzymes; Recombinant proteins; Thrombolytics; Vascular disorder therapies
  • Mechanism of Action Fibrinolytic agents; Plasminogen activator stimulants; Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Catheter thrombosis; Myocardial infarction; Pulmonary embolism; Stroke
  • Phase III Deep vein thrombosis; Haemorrhage
  • Phase II/III SARS-CoV-2 acute respiratory disease

Most Recent Events

  • 25 Jul 2022 Boehringer Ingelheim completes a phase II/III trials in SARS-COV-2 acute respiratory disease in Belgium, Austria, Netherlands, Turkey, Spain, Russia, Romania, Portugal, Poland, Mexico, Malaysia, Italy, India, Germany, France, Denmark, Brazil and Argentina (IV) (NCT04640194) (EudraCT2020-002913-16)
  • 30 Sep 2021 Genentech in collaboration with Denver Health and Hospital Authority completes a phase II clinical trials in SARS-COV-2 acute respiratory disease in USA (IV) (NCT04357730)
  • 04 Aug 2021 Assistance Publique - Hôpitaux de Paris in collaboration with Boerhinger Ingelheim initiates the phase III PEITHO-3 trial in Pulmonary embolism in Austria, France and Germany (NCT04430569) (EudraCT2018-000816-96)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top